$NASDAQ:EDIT

Editas Medicine Stock Fair Value Calculation – Evaluating The Impact Of Editas Medicine’s Approvals Of Casgevy And Lyfgenia
Gallery

Editas Medicine Stock Fair Value Calculation – Evaluating The Impact Of Editas Medicine’s Approvals Of Casgevy And Lyfgenia

🌥️Trending News Editas Medicine ($NASDAQ:EDIT) is a biotechnology company focused on delivering transformative genomic-editing treatments to patients with serious diseases. [...]

By GoodWhale|December 28, 2023|Categories: Biotechnology, Intrinsic Value|Tags: $NASDAQ:EDIT, Biotechnology, NASDAQ|0 Comments

EDITAS MEDICINE Reports 2nd Quarter FY2023 Earnings Results on August 2 2023
Gallery

EDITAS MEDICINE Reports 2nd Quarter FY2023 Earnings Results on August 2 2023

🌥️Earnings Overview On August 2 2023, EDITAS MEDICINE ($NASDAQ:EDIT) reported their financials for the second quarter of FY2023, which ended [...]

By GoodWhale|August 11, 2023|Categories: Biotechnology, Earnings Report|Tags: $NASDAQ:EDIT, Biotechnology, NASDAQ|0 Comments

EDITAS MEDICINE Reports Earnings Results for Second Quarter of Fiscal Year 2023 on June 30
Gallery

EDITAS MEDICINE Reports Earnings Results for Second Quarter of Fiscal Year 2023 on June 30

🌥️Earnings Overview EDITAS ($NASDAQ:EDIT): Net income improved slightly from -53.4 million in the same period in the previous year to [...]

By GoodWhale|August 4, 2023|Categories: Biotechnology, Earnings Report|Tags: $NASDAQ:EDIT, Biotechnology, NASDAQ|0 Comments

Editas Medicine Announces Initial Data for Gene Editing Candidate for Blood Disorders
Gallery

Editas Medicine Announces Initial Data for Gene Editing Candidate for Blood Disorders

🌥️Trending News Editas Medicine ($NASDAQ:EDIT), a leading gene editing company, has recently released the initial data from its groundbreaking gene [...]

By GoodWhale|June 15, 2023|Categories: Biotechnology|Tags: $NASDAQ:EDIT, Biotechnology, NASDAQ|0 Comments

Raymond James Upgrades Editas Medicine to Overweight on its Sickle Cell Candidate
Gallery

Raymond James Upgrades Editas Medicine to Overweight on its Sickle Cell Candidate

🌧️Trending News Raymond James, an investment banking firm, has recently upgraded their rating of Editas Medicine ($NASDAQ:EDIT) to an overweight [...]

By GoodWhale|June 14, 2023|Categories: Biotechnology|Tags: $NASDAQ:EDIT, Biotechnology, NASDAQ|0 Comments

Editas Medicine Leads the Way in Pioneering Gene-Editing Solutions for Inherited Blood Disorders and Beyond
Gallery

Editas Medicine Leads the Way in Pioneering Gene-Editing Solutions for Inherited Blood Disorders and Beyond

Trending News ☀️ Editas Medicine ($NASDAQ:EDIT) is paving the way for gene-editing solutions for hereditary blood disorders and beyond. Through [...]

By GoodWhale|May 6, 2023|Categories: Biotechnology|Tags: $NASDAQ:EDIT, Biotechnology, NASDAQ|0 Comments

Editas Medicine Intrinsic Value Calculator – EDITAS MEDICINE Bolsters Leadership Team with Appointment of Chair and Director
Gallery

Editas Medicine Intrinsic Value Calculator – EDITAS MEDICINE Bolsters Leadership Team with Appointment of Chair and Director

Trending News 🌥️ Editas Medicine ($NASDAQ:EDIT), a leading genome editing company, has made a move to reinforce its leadership team [...]

By GoodWhale|April 14, 2023|Categories: Biotechnology, Intrinsic Value|Tags: $NASDAQ:EDIT, Biotechnology, NASDAQ|0 Comments

Analyzing Analyst Ratings for Editas Medicine (EDIT) Stock
Gallery

Analyzing Analyst Ratings for Editas Medicine (EDIT) Stock

Trending News 🌥️ Analysts' ratings for Editas Medicine ($NASDAQ:EDIT) Inc. (EDIT) stock have been growing steadily in the past several [...]

By GoodWhale|April 4, 2023|Categories: Biotechnology|Tags: $NASDAQ:EDIT, Biotechnology, NASDAQ|0 Comments

EDITAS MEDICINE Reports Fourth Quarter FY2022 Earnings Results on February 22 2023.
Gallery

EDITAS MEDICINE Reports Fourth Quarter FY2022 Earnings Results on February 22 2023.

Earnings report EDITAS MEDICINE ($NASDAQ:EDIT) recently released their fourth quarter FY2022 earnings results, ending December 31 2022, on February 22 [...]